Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs
Plantation, Florida (Newsfile Corp. - June 4, 2021)
Article content
Plantation, Florida–(Newsfile Corp. – May 24, 2021) – Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today their plans for expanding the marketing of their over-the-counter pain relievers and anti-inflammatory products by working with influencers on several social media platforms. These will include celebrities as well as professional and Olympic athletes that have benefitted from Nutra Pharma’s products.
We apologize, but this video has failed to load.
Try refreshing your browser.
Nutra Pharma Corporation: Nutra Pharma is Excited to Announce: Luxury Feet now Available on Amazon finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Nutra Pharma Corporation: Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials
Plantation, Florida (Newsfile Corp. - March 11, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work in improving their existing facilities for manufacturing and validation of their drug products; including their technologies for the treatment of Multiple Sclerosis (MS) and potential countermeasures against nerve agents like sarin gas and VX. As part of this process, Nutra Pharma today announ